Pharma and Healthcare market data, analysis and forecasts from Business Monitor International, the trusted source for business information and industry intelligence across global markets.
Pharma and Healthcare Insight provides market intelligence, trend analysis, forecasts and ratings for the global Pharma and Healthcare industry on a country-by-country basis across the Americas, Emerging Europe, Western Europe, Asia, and the Middle East & Africa. Combined with competitive intelligence on the growth strategies of the leading national and multinational companies, Pharma and Healthcare Insight allows you track key developments across the global Pharma and Healthcare industry.
Subscribers receive password access to the latest intelligence, a searchable 24-month archive of Pharma and Healthcare Insight articles and data plus the ability to download PDFs of current and back issues.
›› To gain FREE online access for 14 days and to download a FREE PDF, click trial.
›› To receive 15 monthly pdf issues for the price of 12 and to gain immediate online access, click subscribe.
To access our feed of headlines copy this link to your RSS reader
Follow Pharma and Healthcare Insight on Twitter
Industry / Ecuador
BMI View: The steadily growing Ecuadorian pharmaceutical market will provide revenue-earning opportunities for Takeda. However, the limited market size and low per capita spending on pharmaceutical products, as well as the country's unorthodox drug regulation policies, may restrict foreign drugmakers' growth opportunities.
2013-03-22Industry
BMI View: Despite the undoubted clinical and commercial success of traditional chemotherapy, demand for new targeted cancer therapies is likely to remain high. This will provide continued...
2013-03-22Industry / United States
BMI View: The outcome of the recent compulsory licence application to manufacture a generic version of Bristol-Myers Squibb (BMS)'s Sprycel (dasatinib) will likely favour the Indian...
2013-03-19Industry / South Korea
The halt of yet another clinical trial for a biosimilar of Roche's Rituxan (rituximab) highlights the regulatory issues biosimilars are currently experiencing. The delay will benefit biologics manufacturers such as Roche, as their market shares will threatened by biosimilars but remain relatively secure for now.
2013-04-29Industry / Japan
Through their involvement in this growing trend, Shionogi, Daiichi Sankyo, Astellas Pharma, Takeda and Eisai can expect to reap huge reputational benefits, as well as access to knowledge...
2013-04-26Industry / Myanmar
We highlight the difficulty Myanmar will face in healthcare financing, given the country's high burden of communicable and non-communicable diseases. The situation is made worse by...
2013-04-25Industry / Russia
The Federal Antimonopoly Service's decision, to block a proposed merger between Abbott Laboratories Petrovax Pharm, while unexpected, does not signal a worsening investment climate in Russia. The country's proximity to the Asia-Pacific region, and seasonal flu pandemics, have influenced the FAS's desire to protect vaccine production in Russia. We note that there is a strong precedence...
2013-04-22Industry / Ukraine
BMI View: The announcement by the health minister that compulsory health insurance is unlikely to be rolled out in the short term is disappointing but not unexpected, given the country's...
2013-04-10Industry / Ukraine
BMI View: Although largely regressive, the impact of the government's move to limit medicine procurement to domestic production will be low, given the small scale of state drug expenditure...
2013-04-09Industry / Ethiopia
The potential for returns on pharmaceutical investment in Ethiopia are great given the large population, favourable demographic and epidemiological trends, as well as its position as a platform to expand into Kenya and Tanzania. However, we highlight the ease with which counterfeit medicines can enter the country due to its proximity to China and India and low per capita medicine...
2013-05-17Industry / Algeria
Although PhRMA is encouraged by the Algerian government's intention to improve its pharmaceutical policies, it is evident that the Ministry of Health continues to make the entire process...
2013-05-16Industry / Lebanon
BMI View: In Lebanon, poor intellectual property protection of innovative medicines is based on the ease with which the Ministry of Health allows generic equivalents to enter the market....
2013-05-15Industry
GlaxoSmithKline (GSK) is a leading global manufacturer of prescription medicines and consumer healthcare products. The company has offices in over 100 countries and major research centres in the UK, US, Belgium and China. GSK's shares are listed on the London and New York Stock Exchanges and its corporate head office is located in the
2013-05-02Industry / Italy
BMI View: Governments across Europe are focussing on cost containment. The consequent scrutiny on drug prices and medicine consumption will subsequently put pressure on companies and...
2013-02-22Industry / Switzerland
BMI View: Novartis' U-turn over CEO Daniel Vasella's exit package could fuel support for a March 3 2013 referendum in Switzerland that proposes changes to Swiss corporate laws, including...
2013-02-20
